<DOC>
	<DOC>NCT01426230</DOC>
	<brief_summary>Study objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice</brief_summary>
	<brief_title>Phase IV Study of FDA Approved, Once-Daily GRALISEâ„¢(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia</brief_title>
	<detailed_description>Open Label, single arm, 2wk titration, 6 wk stable dosing, 8 wk of total treatment, 1wk dose tapering</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<criteria>Men or Women 18 years or older who are suffering from PHN Patient is Pregnant or a nursing mother Patient has hypersensitivity to gabapentin Patient has an estimated creatinine clearance of &lt;30 mL/min or is in hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>PHN</keyword>
	<keyword>Post Herpetic Neuralgia</keyword>
	<keyword>Shingles</keyword>
	<keyword>HZ roster</keyword>
</DOC>